|The full article is available to subscribers||Subscriber Login|
The FDA has approved vedolizumab (Entyvio - Takeda), an intravenous integrin receptor antagonist, for treatment of moderate to severe ulcerative colitis or Crohn's disease in adults who have not responded to, lost response to, or cannot tolerate standard treatment. Natalizumab (Tysabri), another integrin receptor antagonist, has been available for several years for treatment of Crohn's disease and multiple sclerosis.1
STANDARD TREATMENT — Ulcerative Colitis – An aminosalicylate such as mesalamine is generally used first for induction and maintenance of remission in mild to moderate disease. An immunomodulator such as azathioprine or mercaptopurine is often used for maintenance of remission in patients with moderate to severe disease. Oral corticosteroids are effective for inducing remission in patients with moderate disease refractory to other drugs or in those... more
- Natalizumab (Tysabri) for Crohn's disease. Med Lett Drugs Ther 2008; 50:34.
- Drugs for inflammatory bowel disease. Med Lett Drugs Ther 2014; 56:59.
- L Gilroy and PB Allen. Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn's disease? Clin Exp Gastroenterol 2014; 7:163.
- BG Feagan et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369:699.
- S Danese et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med 2014; 160:704.
- WJ Sandborn et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013; 369:711.
- BE Sands et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014; 147:618.